Limula has announced the granting of its key U.S. patent, confirming the company’s leadership in next-generation cell and gene therapy (CGT) manufacturing technologies. The newly granted patent adds to Limula’s growing international IP portfolio, with protection already secured in all other major markets.
The patent covers core innovations in an highly-differentiated platform designed to automate and streamline the production of cell therapies in a single device. Notably, it protects the system’s unique way to integrate multiple functionalities — including cell incubation and cell processing — into a single, closed, and programmable device. This ability to cover all unit operations without transferring cells between modules eliminates the need for multiple tools, reducing footprint, consumable costs and human manual interventions, paving the way for point-of-care manufacturing in hospital settings.
